{"id":26398,"date":"2024-08-12T15:03:17","date_gmt":"2024-08-12T22:03:17","guid":{"rendered":"https:\/\/ameripharmaspecialty.com\/?p=26398"},"modified":"2025-06-04T15:44:49","modified_gmt":"2025-06-04T22:44:49","slug":"ivig-for-b-cell-chronic-lymphocytic-leukemia-cll","status":"publish","type":"post","link":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-b-cell-chronic-lymphocytic-leukemia-cll\/","title":{"rendered":"IgIV para la leucemia linfoc\u00edtica cr\u00f3nica de c\u00e9lulas B (LLC)"},"content":{"rendered":"<p><a href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig\/\/ivig\/\">Inmunoglobulina intravenosa (IVIG)<\/a> La terapia de reemplazo es una medida de apoyo que algunos m\u00e9dicos prescriben a pacientes con leucemia linfoc\u00edtica cr\u00f3nica (LLC) de c\u00e9lulas B cuando tienen <a href=\"https:\/\/ameripharmaspecialty.com\/es\/other-health-conditions\/hypogammaglobulinemia\/\">hipogammaglobulinemia<\/a> (niveles s\u00e9ricos bajos de todos los anticuerpos, como IgG, IgM e IgA) o tienen un alto riesgo de infecciones recurrentes frecuentes.&nbsp;<\/p>\n\n\n\n<div  id=\"call-to-action-5a6eaf88ab894dce3201a7e38a230901\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\tObtenga asistencia para el copago de IgIV\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"tel:8777780318\">(877) 778-0318<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<p>La leucemia linfoc\u00edtica cr\u00f3nica de c\u00e9lulas B (LLC) es un tipo de c\u00e1ncer de sangre que afecta a los linfocitos B, el tipo de gl\u00f3bulos blancos (GB) que producen anticuerpos para combatir infecciones.&nbsp;&nbsp;<\/p>\n\n\n\n<p>Sin embargo, los pacientes con LLC de c\u00e9lulas B no producen anticuerpos funcionales, lo que debilita su sistema inmunol\u00f3gico y los hace muy susceptibles a infecciones virales o bacterianas.&nbsp;<\/p>\n\n\n\n<p>Este art\u00edculo analiza brevemente la leucemia linfoc\u00edtica cr\u00f3nica de c\u00e9lulas B, c\u00f3mo la IgIV puede ayudar a los pacientes que la padecen y qu\u00e9 <a href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig\/\/ivig-brand-reviews\/\">Marcas de IgIV<\/a> Est\u00e1n disponibles para condiciones de LLC de c\u00e9lulas B.&nbsp;<\/p>\n\n\n\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_82_2 counter-hierarchy ez-toc-counter ez-toc-custom ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Alternar tabla de contenido\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Palanca<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewbox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewbox=\"0 0 24 24\" version=\"1.2\" baseprofile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-b-cell-chronic-lymphocytic-leukemia-cll\/#What_Is_B-Cell_Chronic_Lymphocytic_Leukemia_CLL\" >\u00bfQu\u00e9 es la leucemia linfoc\u00edtica cr\u00f3nica de c\u00e9lulas B (LLC)?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-b-cell-chronic-lymphocytic-leukemia-cll\/#Role_of_IVIG_in_B-Cell_Chronic_Lymphocytic_Leukemia_CLL\" >Papel de la IgIV en la leucemia linfoc\u00edtica cr\u00f3nica de c\u00e9lulas B (LLC)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-b-cell-chronic-lymphocytic-leukemia-cll\/#How_Does_IVIG_Work\" >\u00bfC\u00f3mo funciona la IgIV?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-b-cell-chronic-lymphocytic-leukemia-cll\/#Is_There_Any_Specific_Brand_of_IVIG_Available_for_B-Cell_Chronic_Lymphocytic_Leukemia_CLL_Patients\" >\u00bfExiste alguna marca espec\u00edfica de IgIV disponible para pacientes con leucemia linfoc\u00edtica cr\u00f3nica (LLC) de c\u00e9lulas B?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-b-cell-chronic-lymphocytic-leukemia-cll\/#Do_All_B-Cell_Chronic_Lymphocytic_Leukemia_CLL_Patients_Require_IVIG_Therapy\" >\u00bfTodos los pacientes con leucemia linfoc\u00edtica cr\u00f3nica (LLC) de c\u00e9lulas B requieren terapia con IgIV?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-b-cell-chronic-lymphocytic-leukemia-cll\/#Summary\" >Resumen<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\" id=\"h-what-is-b-cell-chronic-lymphocytic-leukemia-cll\"><span class=\"ez-toc-section\" id=\"What_Is_B-Cell_Chronic_Lymphocytic_Leukemia_CLL\"><\/span><strong>\u00bfQu\u00e9 es la leucemia linfoc\u00edtica cr\u00f3nica de c\u00e9lulas B (LLC)?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>La leucemia linfoc\u00edtica cr\u00f3nica de c\u00e9lulas B (LLC) es uno de los tipos m\u00e1s comunes de c\u00e1ncer de sangre, que surge cuando las c\u00e9lulas B cancerosas proliferan a un ritmo inesperado y aumentan en n\u00famero con el tiempo.&nbsp;<\/p>\n\n\n\n<p>Normalmente, en individuos sanos, las c\u00e9lulas madre linfoides se diferencian en linfocitos B maduros y activos que fortalecen el sistema inmunitario y combaten las infecciones. Sin embargo, en personas con LLC de c\u00e9lulas B, las c\u00e9lulas madre linfoides mutadas se diferencian en linfocitos B anormales, que se dividen a\u00fan m\u00e1s y comienzan a acumularse en la m\u00e9dula \u00f3sea, la sangre, los ganglios linf\u00e1ticos, el bazo y el h\u00edgado.&nbsp;<\/p>\n\n\n\n<p>Estos linfocitos B anormales se parecen a las c\u00e9lulas B maduras pero son funcionalmente incompetentes y menos eficaces para combatir infecciones debido a la producci\u00f3n deficiente de anticuerpos.&nbsp;<\/p>\n\n\n\n<p>Adem\u00e1s, a diferencia de las c\u00e9lulas normales, los linfocitos B anormales no experimentan <a href=\"https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/apoptosis\">apoptosis<\/a> (un proceso natural de muerte celular). Debido a esto, un n\u00famero excesivo de c\u00e9lulas B anormales ocupa espacio en la m\u00e9dula \u00f3sea e interfiere con la producci\u00f3n de c\u00e9lulas sangu\u00edneas sanas, como gl\u00f3bulos rojos (GR), plaquetas y leucocitos.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-role-of-ivig-in-b-cell-chronic-lymphocytic-leukemia-cll\"><span class=\"ez-toc-section\" id=\"Role_of_IVIG_in_B-Cell_Chronic_Lymphocytic_Leukemia_CLL\"><\/span><strong>Papel de la IgIV en la leucemia linfoc\u00edtica cr\u00f3nica de c\u00e9lulas B (LLC)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Los pacientes con leucemia linfoc\u00edtica cr\u00f3nica (LLC) de c\u00e9lulas B no producen suficientes anticuerpos funcionales (como IgG) y presentan hipogammaglobulinemia secundaria. Esto los hace m\u00e1s propensos a infecciones recurrentes de los senos paranasales o de los pulmones.&nbsp;<\/p>\n\n\n\n<p>La terapia de reemplazo con IgIV puede ayudar a reducir el n\u00famero de infecciones recurrentes en pacientes con LLC de c\u00e9lulas B. Por ejemplo, una <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/19330654\/\">metaan\u00e1lisis<\/a> Nueve ensayos demostraron que la terapia de reemplazo con IgIV reduce significativamente las infecciones principales en pacientes con LCC.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-how-does-ivig-work\"><span class=\"ez-toc-section\" id=\"How_Does_IVIG_Work\"><\/span><strong>\u00bfC\u00f3mo funciona la IgIV?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"alignright size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"420\" height=\"280\" src=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/ivig-patient.jpg\" alt=\"Patient in chair receiving IVIG therapy\" class=\"wp-image-26401\" srcset=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/ivig-patient.jpg 420w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/ivig-patient-300x200.jpg 300w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/ivig-patient-330x220.jpg 330w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/ivig-patient-86x57.jpg 86w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/ivig-patient-167x111.jpg 167w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/ivig-patient-280x187.jpg 280w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/ivig-patient-370x247.jpg 370w\" sizes=\"auto, (max-width: 420px) 100vw, 420px\" \/><\/figure>\n<\/div>\n\n\n<p>Aunque se desconoce el mecanismo de acci\u00f3n exacto de la terapia con IgIV, los estudios demuestran que ejerce efectos antiinflamatorios y refuerza el sistema inmunitario. En pacientes con LLC de c\u00e9lulas B, la IgIV puede ejercer los siguientes efectos beneficiosos:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Aumenta los niveles de inmunoglobulina s\u00e9rica<\/strong><\/li>\n<\/ul>\n\n\n\n<p>Terapia con IgIV <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8217488\/#:~:text=Overall%2C%20our%20results%20add%20new,cells%20that%20deserves%20further%20investigation.\">aumenta el nivel de inmunoglobulina<\/a> En pacientes con LLC de c\u00e9lulas B e hipogammaglobulinemia secundaria. Esto no solo ayuda a combatir la infecci\u00f3n, sino que tambi\u00e9n reduce la frecuencia y la gravedad de las infecciones en pacientes con LLC de c\u00e9lulas B.&nbsp;<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Ejerce efectos antiinflamatorios<\/strong><\/li>\n<\/ul>\n\n\n\n<p>Adem\u00e1s de reducir la frecuencia de infecciones, la IgIV tambi\u00e9n reduce la inflamaci\u00f3n asociada con la leucemia linfoc\u00edtica cr\u00f3nica de c\u00e9lulas B.&nbsp;<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Reduce los riesgos de complicaciones autoinmunes<\/strong><\/li>\n<\/ul>\n\n\n\n<p>Las complicaciones autoinmunes tambi\u00e9n son comunes en pacientes con LLC de c\u00e9lulas B. En algunos pacientes, se ha observado que las c\u00e9lulas B anormales tambi\u00e9n producen citocinas que inhiben la producci\u00f3n normal de gl\u00f3bulos rojos (GR) y plaquetas, lo que provoca el desarrollo de anemia hemol\u00edtica autoinmune (AHAI) y trombocitopenia inmunitaria (PTI).&nbsp;<\/p>\n\n\n\n<p><a href=\"https:\/\/ameripharmaspecialty.com\/es\/conditions-treatments\/immune-globulin-ig\/\">Terapia con IgIV<\/a> puede ayudar a <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5420315\/#:~:text=Additionally%2C%20CLL%20cells%20produce%20several,development%20of%20AIHA%20and%20ITP.\">reducir los riesgos de anemia hemol\u00edtica (AIHA) y trombocitopenia inmunitaria (ITP) en pacientes con LLC de c\u00e9lulas B<\/a>.<\/p>\n\n\n\n<p>&nbsp;<\/p>\n\n\n\n<div  id=\"call-to-action-fdb1d2c84126ddb4145f0ce5fdd1af5e\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\tObtenga autorizaci\u00f3n previa para IgIV\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"#form\">Programar una consulta<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-is-there-any-specific-brand-of-ivig-available-for-b-cell-chronic-lymphocytic-leukemia-cll-patients\"><span class=\"ez-toc-section\" id=\"Is_There_Any_Specific_Brand_of_IVIG_Available_for_B-Cell_Chronic_Lymphocytic_Leukemia_CLL_Patients\"><\/span><strong>\u00bfExiste alguna marca espec\u00edfica de IgIV disponible para pacientes con leucemia linfoc\u00edtica cr\u00f3nica (LLC) de c\u00e9lulas B?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>S\u00ed, las siguientes son algunas marcas espec\u00edficas de IgIV que se utilizan para tratar la leucemia linfoc\u00edtica cr\u00f3nica de c\u00e9lulas B:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Gammagard SD<\/li>\n\n\n\n<li><a href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/immune-globulin-panzyga\/\">Panzyga<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/bivigam-uses-side-effects-cost-and-more\/\">Vivigam<\/a><\/li>\n\n\n\n<li>Carimune<\/li>\n<\/ul>\n\n\n\n<p>Estos medicamentos de IgIV pueden usarse solos o en combinaci\u00f3n con quimioterapia para tratar la leucemia linfoc\u00edtica cr\u00f3nica de c\u00e9lulas B. Adem\u00e1s, la dosis y la concentraci\u00f3n de cada marca de IgIV difieren. Puede consultar con su profesional de la salud y obtener una receta seg\u00fan su afecci\u00f3n.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-do-all-b-cell-chronic-lymphocytic-leukemia-cll-patients-require-ivig-therapy\"><span class=\"ez-toc-section\" id=\"Do_All_B-Cell_Chronic_Lymphocytic_Leukemia_CLL_Patients_Require_IVIG_Therapy\"><\/span><strong>\u00bfTodos los pacientes con leucemia linfoc\u00edtica cr\u00f3nica (LLC) de c\u00e9lulas B requieren terapia con IgIV?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>No todos los pacientes con leucemia linfoc\u00edtica cr\u00f3nica de c\u00e9lulas B requieren terapia de reemplazo con IgIV. Esta solo se administra si el paciente presenta un nivel bajo de inmunoglobulinas s\u00e9ricas (IgG &lt; 600 mg\/dl) o antecedentes de al menos un episodio de infecci\u00f3n grave en 6 meses.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-summary\"><span class=\"ez-toc-section\" id=\"Summary\"><\/span><strong>Resumen<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>La IgIV es una terapia eficaz que puede ayudar a controlar diversas complicaciones asociadas con la leucemia linfoc\u00edtica cr\u00f3nica de c\u00e9lulas B. Aumenta la concentraci\u00f3n s\u00e9rica de anticuerpos y reduce el riesgo de infecciones recurrentes y enfermedades autoinmunes como la anemia hemol\u00edtica (AHAI) y la trombocitopenia inmunitaria (PTI) en pacientes con leucemia linfoc\u00edtica cr\u00f3nica de c\u00e9lulas B.<\/p>","protected":false},"excerpt":{"rendered":"<p>La terapia de reemplazo de inmunoglobulina intravenosa (IVIG) es una medida de apoyo que algunos m\u00e9dicos prescriben a pacientes con leucemia linfoc\u00edtica cr\u00f3nica (LLC) de c\u00e9lulas B cuando tienen hipogammaglobulinemia (niveles s\u00e9ricos bajos de todos los anticuerpos, como IgG, IgM e IgA) o tienen un alto riesgo de infecciones recurrentes frecuentes.\u00a0<\/p>","protected":false},"author":25,"featured_media":26400,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_uag_custom_page_level_css":"","footnotes":""},"categories":[7],"tags":[31],"class_list":["post-26398","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ivig","tag-dr-mark-alfonso"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>IVIG for B-Cell Chronic Lymphocytic Leukemia (CLL) - AmeriPharma\u00ae Specialty Care<\/title>\n<meta name=\"description\" content=\"Learn about IVIG for B-cell chronic lymphocytic leukemia. Topics include the role of IVIG, how it works, recommended IVIG brands, and more.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-b-cell-chronic-lymphocytic-leukemia-cll\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IVIG for B-Cell Chronic Lymphocytic Leukemia (CLL) - AmeriPharma\u00ae Specialty Care\" \/>\n<meta property=\"og:description\" content=\"Learn about IVIG for B-cell chronic lymphocytic leukemia. Topics include the role of IVIG, how it works, recommended IVIG brands, and more.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-b-cell-chronic-lymphocytic-leukemia-cll\/\" \/>\n<meta property=\"og:site_name\" content=\"AmeriPharma\u00ae Specialty Care\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ameripharma\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-12T22:03:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-04T22:44:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/cll-patient.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"853\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Dr. Mark Alfonso, PharmD, BCMTMS\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dr. Mark Alfonso, PharmD, BCMTMS\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-b-cell-chronic-lymphocytic-leukemia-cll\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-b-cell-chronic-lymphocytic-leukemia-cll\\\/\"},\"author\":{\"name\":\"Dr. Mark Alfonso, PharmD, BCMTMS\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/person\\\/91fbbfa457730010998bc804c0467310\"},\"headline\":\"IVIG for B-Cell Chronic Lymphocytic Leukemia (CLL)\",\"datePublished\":\"2024-08-12T22:03:17+00:00\",\"dateModified\":\"2025-06-04T22:44:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-b-cell-chronic-lymphocytic-leukemia-cll\\\/\"},\"wordCount\":744,\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-b-cell-chronic-lymphocytic-leukemia-cll\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/cll-patient.jpg\",\"keywords\":[\"Dr. Mark Alfonso\"],\"articleSection\":[\"IVIG\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-b-cell-chronic-lymphocytic-leukemia-cll\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-b-cell-chronic-lymphocytic-leukemia-cll\\\/\",\"name\":\"IVIG for B-Cell Chronic Lymphocytic Leukemia (CLL) - AmeriPharma\u00ae Specialty Care\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-b-cell-chronic-lymphocytic-leukemia-cll\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-b-cell-chronic-lymphocytic-leukemia-cll\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/cll-patient.jpg\",\"datePublished\":\"2024-08-12T22:03:17+00:00\",\"dateModified\":\"2025-06-04T22:44:49+00:00\",\"description\":\"Learn about IVIG for B-cell chronic lymphocytic leukemia. Topics include the role of IVIG, how it works, recommended IVIG brands, and more.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-b-cell-chronic-lymphocytic-leukemia-cll\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-b-cell-chronic-lymphocytic-leukemia-cll\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-b-cell-chronic-lymphocytic-leukemia-cll\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/cll-patient.jpg\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/cll-patient.jpg\",\"width\":1280,\"height\":853,\"caption\":\"Patient with B-cell chronic lymphocytic leukemia (CLL)\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-b-cell-chronic-lymphocytic-leukemia-cll\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IVIG for B-Cell Chronic Lymphocytic Leukemia (CLL)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#website\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/\",\"name\":\"AmeriPharma\u00ae Specialty Care\",\"description\":\"Specialty Care by AmeriPharma\",\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#organization\",\"name\":\"Ameripharma Specialty Care\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"width\":400,\"height\":400,\"caption\":\"Ameripharma Specialty Care\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ameripharma\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/person\\\/91fbbfa457730010998bc804c0467310\",\"name\":\"Dr. Mark Alfonso, PharmD, BCMTMS\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/df364e910b779452dd2f50a2c506c7f028521d079f2eb79d89b22b93f4bd45d0?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/df364e910b779452dd2f50a2c506c7f028521d079f2eb79d89b22b93f4bd45d0?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/df364e910b779452dd2f50a2c506c7f028521d079f2eb79d89b22b93f4bd45d0?s=96&d=mm&r=g\",\"caption\":\"Dr. Mark Alfonso, PharmD, BCMTMS\"},\"description\":\"Dr. Mark Alfonso, PharmD was born and raised in Pueblo, CO. He received his pharmacy degree from the University of Colorado School of Pharmacy at the Anschutz Medical Campus in 2010. He was board certified in medication therapy management in 2022. The most rewarding part of his job is helping to answer patient questions and concerns. His areas of expertise are community pharmacy and medication therapy management. In his free time, he enjoys reading and running.\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/author\\\/mark-alfonso\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IgIV para la leucemia linfoc\u00edtica cr\u00f3nica de c\u00e9lulas B (LLC) - AmeriPharma\u00ae Atenci\u00f3n especializada","description":"Aprenda sobre la IgIV para la leucemia linfoc\u00edtica cr\u00f3nica de c\u00e9lulas B. Los temas incluyen la funci\u00f3n de la IgIV, su funcionamiento, las marcas recomendadas de IgIV y m\u00e1s.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-b-cell-chronic-lymphocytic-leukemia-cll\/","og_locale":"es_MX","og_type":"article","og_title":"IVIG for B-Cell Chronic Lymphocytic Leukemia (CLL) - AmeriPharma\u00ae Specialty Care","og_description":"Learn about IVIG for B-cell chronic lymphocytic leukemia. Topics include the role of IVIG, how it works, recommended IVIG brands, and more.","og_url":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-b-cell-chronic-lymphocytic-leukemia-cll\/","og_site_name":"AmeriPharma\u00ae Specialty Care","article_publisher":"https:\/\/www.facebook.com\/ameripharma\/","article_published_time":"2024-08-12T22:03:17+00:00","article_modified_time":"2025-06-04T22:44:49+00:00","og_image":[{"width":1280,"height":853,"url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/cll-patient.jpg","type":"image\/jpeg"}],"author":"Dr. Mark Alfonso, PharmD, BCMTMS","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Dr. Mark Alfonso, PharmD, BCMTMS","Est. reading time":"4 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-b-cell-chronic-lymphocytic-leukemia-cll\/#article","isPartOf":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-b-cell-chronic-lymphocytic-leukemia-cll\/"},"author":{"name":"Dr. Mark Alfonso, PharmD, BCMTMS","@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/person\/91fbbfa457730010998bc804c0467310"},"headline":"IVIG for B-Cell Chronic Lymphocytic Leukemia (CLL)","datePublished":"2024-08-12T22:03:17+00:00","dateModified":"2025-06-04T22:44:49+00:00","mainEntityOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-b-cell-chronic-lymphocytic-leukemia-cll\/"},"wordCount":744,"publisher":{"@id":"https:\/\/ameripharmaspecialty.com\/#organization"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-b-cell-chronic-lymphocytic-leukemia-cll\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/cll-patient.jpg","keywords":["Dr. Mark Alfonso"],"articleSection":["IVIG"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-b-cell-chronic-lymphocytic-leukemia-cll\/","url":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-b-cell-chronic-lymphocytic-leukemia-cll\/","name":"IgIV para la leucemia linfoc\u00edtica cr\u00f3nica de c\u00e9lulas B (LLC) - AmeriPharma\u00ae Atenci\u00f3n especializada","isPartOf":{"@id":"https:\/\/ameripharmaspecialty.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-b-cell-chronic-lymphocytic-leukemia-cll\/#primaryimage"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-b-cell-chronic-lymphocytic-leukemia-cll\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/cll-patient.jpg","datePublished":"2024-08-12T22:03:17+00:00","dateModified":"2025-06-04T22:44:49+00:00","description":"Aprenda sobre la IgIV para la leucemia linfoc\u00edtica cr\u00f3nica de c\u00e9lulas B. Los temas incluyen la funci\u00f3n de la IgIV, su funcionamiento, las marcas recomendadas de IgIV y m\u00e1s.","breadcrumb":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-b-cell-chronic-lymphocytic-leukemia-cll\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-b-cell-chronic-lymphocytic-leukemia-cll\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-b-cell-chronic-lymphocytic-leukemia-cll\/#primaryimage","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/cll-patient.jpg","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/cll-patient.jpg","width":1280,"height":853,"caption":"Patient with B-cell chronic lymphocytic leukemia (CLL)"},{"@type":"BreadcrumbList","@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-b-cell-chronic-lymphocytic-leukemia-cll\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ameripharmaspecialty.com\/es\/"},{"@type":"ListItem","position":2,"name":"IVIG for B-Cell Chronic Lymphocytic Leukemia (CLL)"}]},{"@type":"WebSite","@id":"https:\/\/ameripharmaspecialty.com\/#website","url":"https:\/\/ameripharmaspecialty.com\/","name":"Cuidado especializado AmeriPharma\u00ae","description":"Atenci\u00f3n especializada por AmeriPharma","publisher":{"@id":"https:\/\/ameripharmaspecialty.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ameripharmaspecialty.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/ameripharmaspecialty.com\/#organization","name":"Atenci\u00f3n especializada de Ameripharma","url":"https:\/\/ameripharmaspecialty.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/logo\/image\/","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","width":400,"height":400,"caption":"Ameripharma Specialty Care"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ameripharma\/"]},{"@type":"Person","@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/person\/91fbbfa457730010998bc804c0467310","name":"Dr. Mark Alfonso, PharmD, BCMTMS","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/df364e910b779452dd2f50a2c506c7f028521d079f2eb79d89b22b93f4bd45d0?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/df364e910b779452dd2f50a2c506c7f028521d079f2eb79d89b22b93f4bd45d0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/df364e910b779452dd2f50a2c506c7f028521d079f2eb79d89b22b93f4bd45d0?s=96&d=mm&r=g","caption":"Dr. Mark Alfonso, PharmD, BCMTMS"},"description":"El Dr. Mark Alfonso, doctor en farmacia, naci\u00f3 y creci\u00f3 en Pueblo, Colorado. Obtuvo su t\u00edtulo en farmacia en la Facultad de Farmacia de la Universidad de Colorado, en el Campus M\u00e9dico Anschutz, en 2010. Obtuvo su certificaci\u00f3n en gesti\u00f3n de terapias farmacol\u00f3gicas en 2022. Lo m\u00e1s gratificante de su trabajo es ayudar a responder las preguntas e inquietudes de los pacientes. Sus \u00e1reas de especializaci\u00f3n son la farmacia comunitaria y la gesti\u00f3n de terapias farmacol\u00f3gicas. En su tiempo libre, disfruta de la lectura y correr.","url":"https:\/\/ameripharmaspecialty.com\/es\/author\/mark-alfonso\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/cll-patient.jpg",1280,853,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/cll-patient-150x150.jpg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/cll-patient-300x200.jpg",300,200,true],"medium_large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/cll-patient-768x512.jpg",768,512,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/cll-patient-1024x682.jpg",1024,682,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/cll-patient.jpg",1280,853,false],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/cll-patient.jpg",1280,853,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/cll-patient.jpg",18,12,false],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/cll-patient-600x400.jpg",600,400,true],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/cll-patient-330x220.jpg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/cll-patient-1146x380.jpg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/cll-patient-86x57.jpg",86,57,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/cll-patient-167x111.jpg",167,111,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/cll-patient-280x187.jpg",280,187,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/cll-patient-370x247.jpg",370,247,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/cll-patient-960x640.jpg",960,640,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/cll-patient.jpg",1280,853,false]},"uagb_author_info":{"display_name":"Dr. Mark Alfonso, PharmD, BCMTMS","author_link":"https:\/\/ameripharmaspecialty.com\/es\/author\/mark-alfonso\/"},"uagb_comment_info":0,"uagb_excerpt":"Intravenous immune globulin (IVIG) replacement therapy is a supportive measure that some doctors prescribe to B-cell chronic lymphocytic leukemia (CLL) patients when they have hypogammaglobulinemia (low serum levels of all antibodies, such as IgG, IgM, and IgA) or are at a high risk of frequent recurrent infections.\u00a0","rttpg_featured_image_url":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/cll-patient.jpg",1280,853,false],"landscape":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/cll-patient.jpg",1280,853,false],"portraits":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/cll-patient.jpg",1280,853,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/cll-patient-150x150.jpg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/cll-patient-300x200.jpg",300,200,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/cll-patient-1024x682.jpg",1024,682,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/cll-patient.jpg",1280,853,false],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/cll-patient.jpg",1280,853,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/cll-patient.jpg",18,12,false],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/cll-patient-600x400.jpg",600,400,true],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/cll-patient-330x220.jpg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/cll-patient-1146x380.jpg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/cll-patient-86x57.jpg",86,57,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/cll-patient-167x111.jpg",167,111,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/cll-patient-280x187.jpg",280,187,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/cll-patient-370x247.jpg",370,247,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/cll-patient-960x640.jpg",960,640,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/08\/cll-patient.jpg",1280,853,false]},"rttpg_author":{"display_name":"Dr. Mark Alfonso, PharmD, BCMTMS","author_link":"https:\/\/ameripharmaspecialty.com\/es\/author\/mark-alfonso\/"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/ameripharmaspecialty.com\/es\/category\/ivig\/\" rel=\"category tag\">IVIG<\/a>","rttpg_excerpt":"Intravenous immune globulin (IVIG) replacement therapy is a supportive measure that some doctors prescribe to B-cell chronic lymphocytic leukemia (CLL) patients when they have hypogammaglobulinemia (low serum levels of all antibodies, such as IgG, IgM, and IgA) or are at a high risk of frequent recurrent infections.\u00a0","_links":{"self":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts\/26398","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/users\/25"}],"replies":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/comments?post=26398"}],"version-history":[{"count":0,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts\/26398\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/media\/26400"}],"wp:attachment":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/media?parent=26398"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/categories?post=26398"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/tags?post=26398"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}